Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes

<i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study

New England Journal of Medicine · 2008 · 2K citations · Full text

The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects

Deepak Voora, Svati H. Shah, Ivan Spasojević et al. · Journal of the American College of Cardiology · 2009 · 502 citations

Genetics, Genetic Factor, Medicine +3

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

Marja K. Pasanen, Mikko Neuvonen, Pertti J. Neuvonen et al. · Pharmacogenetics and Genomics · 2006 · 461 citations

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

Aleksi Tornio, Juha Vakkilainen, Mikko Neuvonen et al. · Pharmacogenetics and Genomics · 2015 · 406 citations

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

Russell A. Wilke, Laura B. Ramsey, Samuel G. Johnson et al. · Clinical Pharmacology & Therapeutics · 2012 · 324 citations · Full text